Back

Risk stratified effect of beta-blockers after myocardial infarction in patients without heart failure: A substudy of the BETAMI-DANBLOCK trial

25 April 2026 (09:30 - 10:15)
Organised by: Logo
Congress Presentation Part of: Risk management in acute coronary syndrome Prevention EAPC Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Harun Caglar

Bispebjerg Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
Impact of coronavirus disease 19 (COVID-19) pandemic on age differences of acute coronary syndromes admissions and in-hospital outcomes
Doctor E. Tafaj (Tirana, AL)
Abstract Slides
Presentation thumbnail
Changes in mortality due to acute myocardial infarction in poland in comparison with selected european union countries between 2000 and 2022; insights for cardiovascular prevention
Associate Professor M. Burzynska (Lodz, PL)
Abstract Slides
Presentation thumbnail
The missing momentum: a prospective analysis of early post-discharge retention and optimisation of guideline-directed medical therapy after acute coronary syndromes in a tertiary cardiac centre
Mrs A. Iordanescu (Plymouth, GB)
Abstract Slides
Presentation thumbnail
Beta-blocker therapy and sleep disturbances after myocardial infarction: a prespecified sub-study of the BETAMI-DANBLOCK trial
Mrs J. Nyen (Drammen, NO)
Abstract Slides

Access the full session

Session thumbnail
Risk management in acute coronary syndrome

The Event

Event poster

ESC Preventive Cardiology 2026

25 April 2026 09:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources